Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson’s disease management in developing countries

References

• Pagaiya N, Phanthunane P, Bamrung A, et al. Forecasting imbalances of human resources for health in the Thailand health service system: application of a health demand method. Hum Resour Health. 2019;17(1):4.
   PubMedGoogle Scholar
• Tangcharoensathien V, Patcharanarumol W, Kulthanmanusorn A, et al. The political economy of UHC reform in Thailand: lessons for low- and middle-income countries. Health Syst Reform. 2019;5(3):195–208.
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–386.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(5):459–480.
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Sherer T, Okun MS, et al. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(s1):S3–S8.
   PubMedGoogle Scholar
• Lesko CR, Jacobson LP, Althoff KN, et al. Collaborative, pooled and harmonized study designs for epidemiologic research: challenges and opportunities. Int J Epidemiol. 2018;47(2):654–668.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Wannachai N, Limpabandhu S, et al. A national registry to determine the distribution and prevalence of Parkinson’s disease in Thailand: implications of urbanization and pesticides as risk factors for Parkinson’s disease. Neuroepidemiology. 2011;37(3–4):222–230.
   PubMed Web of Science ®Google Scholar
• Tangamornsuksan W, Lohitnavy O, Sruamsiri R, et al. Paraquat exposure and Parkinson’s disease: a systematic review and meta-analysis. Arch Environ Occup Health. 2019;74(5):225–238.
   PubMed Web of Science ®Google Scholar
• Tan AH, Tan CT, Marras C, et al. Knowledge of Parkinson’s disease in a multiethnic urban asian setting. J Parkinsons Dis. 2015;5(4):865–879.
   PubMedGoogle Scholar
• Chaudhuri KR, Bhidayasiri R, van Laar T. Unmet needs in Parkinson’s disease: new horizons in a changing landscape. Parkinsonism Relat Disord. 2016;33(Suppl 1):S2–S8.
   PubMedGoogle Scholar
• Fasano A, Visanji NP, Liu LW, et al. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14(6):625–639.
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Curr Treat Options Neurol. 2018;20(12):54.
   PubMed Web of Science ®Google Scholar
• Ray Chaudhuri K, Qamar MA, Rajah T, et al. Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future. NPJ Parkinsons Dis. 2016;2:16023.
   PubMed Web of Science ®Google Scholar
• Poewe W, Seppi K, Marini K, et al. New hopes for disease modification in Parkinson’s disease. Neuropharmacology. 2020;171:108085.
   PubMed Web of Science ®Google Scholar
• Cilia R, Akpalu A, Sarfo FS, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(Pt 10):2731–2742.
   PubMed Web of Science ®Google Scholar
• Bjornestad A, Forsaa EB, Pedersen KF, et al. Risk and course of motor complications in a population-based incident Parkinson’s disease cohort. Parkinsonism Relat Disord. 2016;22:48–53.
   PubMed Web of Science ®Google Scholar
• Titova N, Martinez-Martin P, Katunina E, et al. Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed. J Neural Transm (Vienna). 2017;124(12):1529–1537.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Rosa MM, Ferreira JJ. Adjunctive therapies in Parkinson’s disease: how to choose the best treatment strategy approach. Drugs Aging. 2018;35(12):1041–1054.
   PubMed Web of Science ®Google Scholar
• Antonini A, Stoessl AJ, Kleinman LS, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063–2073.
   PubMed Web of Science ®Google Scholar
• Lee J, Kim Y, Kim S, et al. Unmet needs of people with Parkinson’s disease: a cross-sectional study. J Adv Nurs. 2019;75(12):3504–3514.
   PubMed Web of Science ®Google Scholar
• Perrin PB, Henry RS, Donovan EK, et al. Parkinson’s family needs and caregiver mental health: a cross-cultural comparison between Mexico and the United States. NeuroRehabilitation. 2019;45(4):433–442.
   PubMed Web of Science ®Google Scholar
• Read J, Cable S, Lofqvist C, et al. Experiences of health services and unmet care needs of people with late-stage Parkinson’s in England: a qualitative study. PloS One. 2019;14(12):e0226916.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Panyakaew P, Trenkwalder C, et al. Delivering patient-centered care in Parkinson’s disease: challenges and consensus from an international panel. Parkinsonism Relat Disord. 2020;72:82–87.
   PubMed Web of Science ®Google Scholar
• Qamar MA, Harington G, Trump S, et al. Multidisciplinary care in Parkinson’s disease. Int Rev Neurobiol. 2017;132:511–523.
   PubMed Web of Science ®Google Scholar
• van der Marck MA, Bloem BR, Borm GF, et al. Effectiveness of multidisciplinary care for Parkinson’s disease: a randomized, controlled trial. Mov Disord. 2013;28(5):605–611.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Saksornchai K, Kaewwilai L, et al. A census of movement disorders at a Thai university hospital. J Neurol Sci. 2011;301(1–2):31–34.
   PubMed Web of Science ®Google Scholar
• van der Marck MA, Munneke M, Mulleners W, et al. Integrated multidisciplinary care in Parkinson’s disease: a non-randomised, controlled trial (IMPACT). Lancet Neurol. 2013;12(10):947–956.
   PubMed Web of Science ®Google Scholar
• Marumoto K, Yokoyama K, Inoue T, et al. Inpatient enhanced multidisciplinary care effects on the quality of life for Parkinson disease: a quasi-randomized controlled trial. J Geriatr Psychiatry Neurol. 2019;32(4):186–194.
   PubMed Web of Science ®Google Scholar
• Radder DLM, Lennaerts HH, Vermeulen H, et al. The cost-effectiveness of specialized nursing interventions for people with Parkinson’s disease: the NICE-PD study protocol for a randomized controlled clinical trial. Trials. 2020;21(1):88.
   PubMed Web of Science ®Google Scholar
• Lennaerts H, Groot M, Rood B, et al. A guideline for Parkinson’s disease nurse specialists, with recommendations for clinical practice. J Parkinsons Dis. 2017;7(4):749–754.
   PubMedGoogle Scholar
• Willis AW, Schootman M, Evanoff BA, et al. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology. 2011;77(9):851–857.
   PubMed Web of Science ®Google Scholar
• Willis AW, Schootman M, Tran R, et al. Neurologist-associated reduction in PD-related hospitalizations and health care expenditures. Neurology. 2012;79(17):1774–1780.
   PubMed Web of Science ®Google Scholar
• Sakdisornchai K, Bhidayasiri R, Jitkritsadakul O, et al. Availability of anti-parkinsonian drugs in Thailand. Mov Disord. 2017;32(2):S512–S514.
   Google Scholar
• Bhidayasiri R, Hattori N, Jeon B, et al. Asian perspectives on the recognition and management of levodopa ‘wearing-off’ in Parkinson’s disease. Expert Rev Neurother. 2015;15(11):1285–1297.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Suthisisung J, Sringean J, et al. Thai National Formulary 2019: drugs used in Parkinson’s disease. Bangkok: Food and Drug Administration of Thailand; 2019.
   Google Scholar
• Bhidayasiri R, Ling H. Treatment of Parkinson’s disease in Thailand: review of the literature and practical recommendations. J Med Assoc Thai. 2009;92(1):142–154.
   PubMedGoogle Scholar
• Nunta-Aree S, Sitthinamsuwan B, Boonyapisit K, et al. SW2-year outcomes of subthalamic deep brain stimulation for idiopathic Parkinson’s disease. J Med Assoc Thai. 2010;93(5):529–540.
   PubMedGoogle Scholar
• Antonini A, Moro E, Godeiro C, et al. Medical and surgical management of advanced Parkinson’s disease. Mov Disord. 2018;33(6):900–908.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Chaudhuri KR, Garcia Ruiz PJ, et al. Expert consensus group report on the use of apomorphine in the treatment of Parkinson’s disease–clinical practice recommendations. Parkinsonism Relat Disord. 2015;21(9):1023–1030.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Chaudhuri KR, LeWitt P, et al. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses. Clin Neuropharmacol. 2015;38(3):89–103.
   PubMed Web of Science ®Google Scholar
• Unti E, Ceravolo R, Bonuccelli U. Apomorphine hydrochloride for the treatment of Parkinson’s disease. Expert Rev Neurother. 2015;15(7):723–732.
   PubMed Web of Science ®Google Scholar
• Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord. 2002;17(6):1235–1241.
   PubMed Web of Science ®Google Scholar
• Auffret M, Drapier S, Verin M. Pharmacological insights into the use of apomorphine in Parkinson’s disease: clinical relevance. Clin Drug Investig. 2018;38(4):287–312.
   PubMed Web of Science ®Google Scholar
• Jenner P, Katzenschlager R. Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease. Parkinsonism Relat Disord. 2016;33(Suppl 1):S13–S21.
   PubMedGoogle Scholar
• Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17(9):749–759.
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33(8):1248–1266.
   PubMed Web of Science ®Google Scholar
• Antonini A, Jenner P. Apomorphine infusion in advanced Parkinson disease. Nat Rev Neurol. 2018;14(12):693–694.
   PubMed Web of Science ®Google Scholar
• Gershanik O, Jenner P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson’s disease. Eur J Neurol. 2012;19(12):1502–1508.
   PubMed Web of Science ®Google Scholar
• Timpka J, Henriksen T, Odin P. Non-oral continuous drug delivery techniques in Parkinson’s disease: for whom, when, and how? Mov Disord Clin Pract. 2016;3(3):221–229.
   PubMed Web of Science ®Google Scholar
• Odin P, Ray Chaudhuri K, Slevin JT, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21(10):1133–1144.
   PubMed Web of Science ®Google Scholar
• Buhmann C, Hilker R, Lingor P, et al. Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. J Neural Transm (Vienna). 2017;124(8):1005–1013.
   PubMed Web of Science ®Google Scholar
• Dafsari HS, Martinez-Martin P, Rizos A, et al. EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease. Mov Disord. 2019;34(3):353–365.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Parkinson’s disease in adults 2017. 2017.
   Google Scholar
• Bhidayasiri R, Boonpang K, Jitkritsadakul O, et al. Understanding the role of the Parkinson’s disease nurse specialist in the delivery of apomorphine therapy. Parkinsonism Relat Disord. 2016;33(Suppl 1):S49–S55.
   PubMedGoogle Scholar
• Bhidayasiri R, Phokaewvarangkul O, Boonpang K, et al. Long-term apomorphine infusion users versus short-term users: an international dual-center analysis of the reasons for discontinuing therapy. Clin Neuropharmacol. 2019;42(5):172–178.
   PubMed Web of Science ®Google Scholar
• Henriksen T. Clinical insights into use of apomorphine in Parkinson’s disease: tools for clinicians. Neurodegener Dis Manag. 2014;4(3):271–282.
   PubMedGoogle Scholar
• Williams DR, Evans AH, Fung VSC, et al. Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia. Intern Med J. 2017;47(10):1107–1113.
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord. 2008;23(8):1130–1136.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Garcia Ruiz PJ, Henriksen T. Practical management of adverse events related to apomorphine therapy. Parkinsonism Relat Disord. 2016;33(Suppl 1):S42–S48.
   PubMedGoogle Scholar
• Poltawski L, Edwards H, Todd A, et al. Cutaneous side effects of infused apomorphine: the patient and carer experience. Br J Neurosci Nurs. 2008;4:576–580.
   Google Scholar
• Borgemeester RW, Drent M, van Laar T. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson’s disease patients. Parkinsonism Relat Disord. 2016;23:17–22.
   PubMed Web of Science ®Google Scholar
• Sesar A, Fernandez-Pajarin G, Ares B, et al. Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients. J Neurol. 2017;264(5):946–954.
   PubMed Web of Science ®Google Scholar
• Kimber TE, Fang J, Huddy LJ, et al. Long-term adherence to apomorphine infusion in patients with Parkinson disease: a 10-year observational study. Intern Med J. 2017;47(5):570–573.
   PubMed Web of Science ®Google Scholar
• Lim SY, Tan AH, Ahmad-Annuar A, et al. Parkinson’s disease in the Western Pacific Region. Lancet Neurol. 2019;18:865–879.
   Web of Science ®Google Scholar
• Taleb N, Messier V, Ott-Braschi S, et al. Perceptions and experiences of adult patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: results of an online survey. Diabetes Res Clin Pract. 2018;144:42–50.
   PubMed Web of Science ®Google Scholar
• Titova N, Chaudhuri KR. Personalized medicine in Parkinson’s disease: time to be precise. Mov Disord. 2017;32(8):1147–1154.
   PubMed Web of Science ®Google Scholar
• Jitkritsadakul O, Boonrod N, Bhidayasiri R. Knowledge, attitudes and perceptions of Parkinson’s disease: a cross-sectional survey of Asian patients. J Neurol Sci. 2017;374:69–74.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Brenden N, Viwattanakulvanid P, et al. Identifying gaps in knowledge about Parkinson disease among medical professionals in Thailand. Neurology. 2014;82(24):2238–2240.
   PubMed Web of Science ®Google Scholar
• Thompson MR, Stone RF, Dan Ochs V, et al. Primary health care providers’ knowledge gaps on Parkinson’s disease. Educ Gerontol. 2013;39(11):856–862.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Phokaewvarangkul O, Boonpang K, et al. Establishing the first apomorphine treatment registry in Thailand: prospective data collection to inform optimal care of Parkinson’s disease patients.. Mov Disord. 2019;34:S740.
   Web of Science ®Google Scholar
• Dotchin C, Walker R. The management of Parkinson’s disease in sub-Saharan Africa. Expert Rev Neurother. 2012;12(6):661–666.
   PubMed Web of Science ®Google Scholar
• Ragothaman M, Govindappa ST, Rattihalli R, et al. Direct costs of managing Parkinson’s disease in India: concerns in a developing country. Mov Disord. 2006;21(10):1755–1758.
   PubMed Web of Science ®Google Scholar
• Bovolenta TM, de Azevedo Silva SMC, Saba RA, et al. Average annual cost of Parkinson’s disease in Sao Paulo, Brazil, with a focus on disease-related motor symptoms. Clin Interv Aging. 2017;12:2095–2108.
   PubMed Web of Science ®Google Scholar
• Radder DLM, de Vries NM, Riksen NP, et al. Multidisciplinary care for people with Parkinson’s disease: the new kids on the block! Expert Rev Neurother. 2019;19(2):145–157.
   PubMed Web of Science ®Google Scholar
• Skelly R, Lindop F, Johnson C. Multidisciplinary care of patients with Parkinson’s disease. Prog Neurol Psychiatry. 2012;16(2):10–14.
   Google Scholar
• Jones B, Hopkins G, Wherry SA, et al. Evaluation of a Regional Australian Nurse-Led Parkinson’s Service Using the Context, Input, Process, and Product Evaluation Model. Clin Nurse Spec. 2016;30(5):264–270.
   PubMed Web of Science ®Google Scholar
• Cotterell P. Parkinson’s disease: symptoms, treatment options and nursing care. Nurs Stand. 2018;33(7):53–58.
   PubMedGoogle Scholar
• Surendranath S. Parkinson’s nurses: a light in the darkness. Nurs Older People. 2014;26(9):16–20.
   PubMedGoogle Scholar
• van der Eijk M, Nijhuis FA, Faber MJ, et al. Moving from physician-centered care towards patient-centered care for Parkinson’s disease patients. Parkinsonism Relat Disord. 2013;19(11):923–927.
   PubMed Web of Science ®Google Scholar
• Choo XY, Lim SY, Chinna K, et al. Understanding patients’ and caregivers’ perspectives and educational needs in Parkinson’s disease: a multi-ethnic Asian study. Neurol Sci. 2020. [ Epub ahead of print]. DOI:10.1007/s10072-020-04396-4
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Voss TS, Shprecher DR, et al. A U.S. survey of patients with Parkinson’s disease: satisfaction with medical care and support groups. Mov Disord. 2010;25(13):2128–2135.
   PubMed Web of Science ®Google Scholar
• Henry RS, Lageman SK, Perrin PB. The relationship between Parkinson’s disease symptoms and caregiver quality of life. Rehabil Psychol. 2020;65(2):137–144.
   PubMed Web of Science ®Google Scholar
• Tessitore A, Marano P, Modugno N, et al. Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study. J Neurol. 2018;265(5):1124–1137.
   PubMed Web of Science ®Google Scholar
• Viwattanakulvanid P, Kaewwilai L, Jitkritsadakul O, et al. The impact of the nocturnal disabilities of Parkinson’s disease on caregivers’ burden: implications for interventions. J Neural Transm. 2014;121(Suppl 1):15–24.
   PubMedGoogle Scholar
• World Medical Association Declaration of Lisbon on the Rights of the Patients. In: The 34th world medical assembly. (Ed.^(Eds) Lisbon, Portugal; 1981.
   Google Scholar
• Gupta HV, Lyons KE, Pahwa R. Old Drugs, New Delivery Systems in Parkinson’s Disease. Drugs Aging. 2019;36(9):807–821.
   PubMed Web of Science ®Google Scholar
• Espay AJ, Hausdorff JM, Sanchez-Ferro A, et al. A roadmap for implementation of patient-centered digital outcome measures in Parkinson’s disease obtained using mobile health technologies. Mov Disord. 2019;34(5):657–663.
   PubMed Web of Science ®Google Scholar
• Ben-Pazi H, Browne P, Chan P, et al. The promise of telemedicine for movement disorders: an interdisciplinary approach. Curr Neurol Neurosci Rep. 2018;18(5):26.
   PubMed Web of Science ®Google Scholar